• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom readies $750m debt offering

November 27, 2018 By Sarah Faulkner

DexcomDexcom (NSDQ:DXCM) said yesterday that it plans to offer $750 million in convertible senior notes due 2023 in a private placement to institutional buyers.

The San Diego, Calif.-based company also expects to give buyers a 13-day option to buy up to an additional $100 million aggregate principal amount of notes.

The notes will mature on Dec. 1, 2023, Dexcom reported in an SEC filing. The company plans to use up to $100 million of the net proceeds to repurchase shares, as well as pay the cost of the convertible hedge transactions that it expects to enter into with one or more of the initial purchasers of the notes.

The rest of the offering’s net proceeds will be used for working capital and general corporate purposes, Dexcom said.

Earlier this month, Dexcom announced that it would pay $250 million upfront in stock to Verily in an amended collaboration and licensing deal.

The two companies are working to develop a second-generation continuous glucose monitoring system. The updated deal also notes that the companies could collaborate on additional products and software.

The new agreement structure makes Dexcom the preferred CGM device supplier for Verily’s Onduo franchise and its Type 2 diabetes management program, the company added. According to the terms of the deal, Dexcom is slated to make an upfront payment of $250 million in shares of its common stock, with additional milestones of up to $280 million contingent upon product launch and revenue milestones.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Business/Financial News, Diabetes, Featured, Funding Roundup, Wall Street Beat Tagged With: DexCom Inc.

IN CASE YOU MISSED IT

  • BD stock up on Street-beating preliminary quarterly revenue numbers
  • Locate Bio lands FDA breakthrough nod for bone infection device
  • PerkinElmer to acquire Oxford Immunotec
  • Evonik buys polymers business from Durect Corp.
  • New Croatian notified body designated to European MDR

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS